Skip to main content
Figure 3 | BMC Cancer

Figure 3

From: N-benzyladriamycin-14-valerate (AD 198) exhibits potent anti-tumor activity on TRAF3-deficient mouse B lymphoma and human multiple myeloma

Figure 3

AD 198 and oridonin exhibited potent anti-tumor activity on transplanted TRAF3 -/- B lymphomas in NOD SCID mice. TRAF3-/- mouse B lymphoma cell line 27–9.5.3 cells (3 x 106 per mouse) were i.p. injected into NOD SCID recipient mice. On day 2 post transplantation, mice were divided into 3 cohorts for administration with drugs or with vehicle. Mice were i.p. injected with 150 μl (for a 20 g mouse) of AD 198 (5 mg/kg, n = 8), oridonin (7.5 mg/kg, n = 6), or vehicle (90% PBS and 10% DMSO; CTL, n = 12). Drug or vehicle injections were carried out three times a week for 2 weeks. Transplanted NOD SCID mice were monitored daily for tumor development as described in the Methods. Survival curves of mice were generated using the Kaplan-Meier method. P value of AD 198 vs. CTL is <0.0001, and P value of oridonin vs. CTL is 0.0043, as determined by the Mantel-Cox log-rank test.

Back to article page